Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and ...

There are many reasons why investors choose to stay away from stocks during and close to earnings announcements, one of them ...

New York, New York-- (Newsfile Corp. - March 3, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX) ...

America's Clean Energy CompanyTM, today announced its financial and operational results for the fiscal year ended December 31 ...